of the vaccine all seroconverted within 15 days of a single dose, which means that they produced antibodies. Two weeks after receiving a second dose, people who received the smallest-tested dose of the vaccine created levels of binding antibodies equivalent to those seen in people who have recovered from Covid-19. And people who received a medium dose of the vaccine produced binding antibodies two weeks after a second dose that significantly exceeded the levels seen in recovered patients, the company said…
Moderna also released data about the levels of neutralizing antibodies in eight trial subjects. In those people, the level of neutralizing antibodies two weeks after a second dose, which were tested against live virus, was at or above levels seen in recovered patients.
Moderna said the vaccine appeared to be safe and well tolerated in its human subjects, a total of 45 people.
